Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally adv...
- Autores:
-
Castillo Molina, David
Fierro Lozada, Jesus Daniel
García C., Ana María
Molano Pérez, Manuela Alejandra
Cantillo Avilez, Melissa
Guerrero Roncancio, Laura
Muñoz-Ordoñez, Sara
Campo Slebi, Isabella
ALVIS-ZAKZUK, NELSON J.
Castillo Saavedra, David E.
Martinez Zuñiga, Diego M.
Alvis Zakzuk, Nelson J.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Corporación Universidad de la Costa
- Repositorio:
- REDICUC - Repositorio CUC
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.cuc.edu.co:11323/9307
- Acceso en línea:
- https://hdl.handle.net/11323/9307
https://doi.org/10.1016/j.jaad.2021.06.541
https://repositorio.cuc.edu.co/
- Palabra clave:
- Cryotherapy
Vismodegib
Basal cell carcinoma
- Rights
- openAccess
- License
- © 2021 Published by Elsevier Inc.
id |
RCUC2_c3c6262925e30c5da9554267e7059dcd |
---|---|
oai_identifier_str |
oai:repositorio.cuc.edu.co:11323/9307 |
network_acronym_str |
RCUC2 |
network_name_str |
REDICUC - Repositorio CUC |
repository_id_str |
|
dc.title.eng.fl_str_mv |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
title |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
spellingShingle |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases Cryotherapy Vismodegib Basal cell carcinoma |
title_short |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
title_full |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
title_fullStr |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
title_full_unstemmed |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
title_sort |
Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases |
dc.creator.fl_str_mv |
Castillo Molina, David Fierro Lozada, Jesus Daniel García C., Ana María Molano Pérez, Manuela Alejandra Cantillo Avilez, Melissa Guerrero Roncancio, Laura Muñoz-Ordoñez, Sara Campo Slebi, Isabella ALVIS-ZAKZUK, NELSON J. Castillo Saavedra, David E. Martinez Zuñiga, Diego M. Alvis Zakzuk, Nelson J. |
dc.contributor.author.spa.fl_str_mv |
Castillo Molina, David Fierro Lozada, Jesus Daniel García C., Ana María Molano Pérez, Manuela Alejandra Cantillo Avilez, Melissa Guerrero Roncancio, Laura Muñoz-Ordoñez, Sara Campo Slebi, Isabella ALVIS-ZAKZUK, NELSON J. Castillo Saavedra, David E. Martinez Zuñiga, Diego M. |
dc.contributor.author.none.fl_str_mv |
Alvis Zakzuk, Nelson J. |
dc.subject.proposal.eng.fl_str_mv |
Cryotherapy Vismodegib Basal cell carcinoma |
topic |
Cryotherapy Vismodegib Basal cell carcinoma |
description |
Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally advanced and unresectable. We described the response of patients treated with vismodegib and cryotherapy as adjuvant management. Materials and methods: We conducted an observational retrospective study in a dermatologic center in Bogota, Colombia. We included patients with BCC diagnosis and were treated with vismodegib and cryotherapy from January 2018 to August 2020. Variables included age, sex, phototype, lesion location, treatment duration, number of cryotherapies, months of follow-up, and histologic subtypes. Variables were analyzed using Microsoft Excel 2016. Results: Of eight patients reviewed, four were female. Median age was 70 years old. Photoype III was the most frequent. Zone H was the most affected location. The mean number of cryotherapy sessions received during vismodegib treatment was 4.75, and the mean duration of treatment with the hedgehog inhibitor was 3.5 months. Patients were followed up for 15.57 months. Of the eight patients, four presented nodular pattern histology, in the rest the mixed subtype predominated. Conclusion: In general, there was a good response to treatment with a notable decrease in the size and control of the lesions. No side effects were described during the follow-up time; however, the patients will continue to be under strict controls. |
publishDate |
2021 |
dc.date.issued.none.fl_str_mv |
2021-09-01 |
dc.date.accessioned.none.fl_str_mv |
2022-06-24T13:44:49Z |
dc.date.available.none.fl_str_mv |
2022-06-24T13:44:49Z |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
acceptedVersion |
dc.identifier.citation.spa.fl_str_mv |
David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541. |
dc.identifier.issn.spa.fl_str_mv |
0190-9622 |
dc.identifier.uri.spa.fl_str_mv |
https://hdl.handle.net/11323/9307 |
dc.identifier.url.spa.fl_str_mv |
https://doi.org/10.1016/j.jaad.2021.06.541 |
dc.identifier.doi.spa.fl_str_mv |
10.1016/j.jaad.2021.06.541 |
dc.identifier.eissn.spa.fl_str_mv |
1097-6787 |
dc.identifier.instname.spa.fl_str_mv |
Corporación Universidad de la Costa |
dc.identifier.reponame.spa.fl_str_mv |
REDICUC - Repositorio CUC |
dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.cuc.edu.co/ |
identifier_str_mv |
David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541. 0190-9622 10.1016/j.jaad.2021.06.541 1097-6787 Corporación Universidad de la Costa REDICUC - Repositorio CUC |
url |
https://hdl.handle.net/11323/9307 https://doi.org/10.1016/j.jaad.2021.06.541 https://repositorio.cuc.edu.co/ |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofjournal.spa.fl_str_mv |
Journal of the American Academy of Dermatology |
dc.relation.citationissue.spa.fl_str_mv |
3 |
dc.relation.citationvolume.spa.fl_str_mv |
85 |
dc.rights.spa.fl_str_mv |
© 2021 Published by Elsevier Inc. Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
© 2021 Published by Elsevier Inc. Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.extent.spa.fl_str_mv |
1 página |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Mosby Inc. |
dc.publisher.place.spa.fl_str_mv |
United States |
institution |
Corporación Universidad de la Costa |
dc.source.url.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0190962221016455?via%3Dihub |
bitstream.url.fl_str_mv |
https://repositorio.cuc.edu.co/bitstreams/53955e25-4c5f-4624-935f-8dab9832dedc/download https://repositorio.cuc.edu.co/bitstreams/5439741f-4f1d-4c9b-8938-853c3947c3e9/download https://repositorio.cuc.edu.co/bitstreams/6a2e081b-1745-4b4a-9586-92dff3368e99/download https://repositorio.cuc.edu.co/bitstreams/8428aa3c-b116-43b8-8fac-b3d13a027389/download |
bitstream.checksum.fl_str_mv |
550e3522ec17a3d3d54c52a37d12b17d e30e9215131d99561d40d6b0abbe9bad 472acd6d7e08130ceaf0b9fbcf350780 0f3750738f93bd00c645a6162cde60e7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio de la Universidad de la Costa CUC |
repository.mail.fl_str_mv |
repdigital@cuc.edu.co |
_version_ |
1828166908053028864 |
spelling |
Castillo Molina, DavidFierro Lozada, Jesus DanielGarcía C., Ana MaríaMolano Pérez, Manuela AlejandraCantillo Avilez, MelissaGuerrero Roncancio, LauraMuñoz-Ordoñez, SaraCampo Slebi, IsabellaALVIS-ZAKZUK, NELSON J.Castillo Saavedra, David E.Martinez Zuñiga, Diego M.Alvis Zakzuk, Nelson J.virtual::251-12022-06-24T13:44:49Z2022-06-24T13:44:49Z2021-09-01David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541.0190-9622https://hdl.handle.net/11323/9307https://doi.org/10.1016/j.jaad.2021.06.54110.1016/j.jaad.2021.06.5411097-6787Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally advanced and unresectable. We described the response of patients treated with vismodegib and cryotherapy as adjuvant management. Materials and methods: We conducted an observational retrospective study in a dermatologic center in Bogota, Colombia. We included patients with BCC diagnosis and were treated with vismodegib and cryotherapy from January 2018 to August 2020. Variables included age, sex, phototype, lesion location, treatment duration, number of cryotherapies, months of follow-up, and histologic subtypes. Variables were analyzed using Microsoft Excel 2016. Results: Of eight patients reviewed, four were female. Median age was 70 years old. Photoype III was the most frequent. Zone H was the most affected location. The mean number of cryotherapy sessions received during vismodegib treatment was 4.75, and the mean duration of treatment with the hedgehog inhibitor was 3.5 months. Patients were followed up for 15.57 months. Of the eight patients, four presented nodular pattern histology, in the rest the mixed subtype predominated. Conclusion: In general, there was a good response to treatment with a notable decrease in the size and control of the lesions. No side effects were described during the follow-up time; however, the patients will continue to be under strict controls.1 páginaapplication/pdfengMosby Inc.United States© 2021 Published by Elsevier Inc.Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 casesArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionhttps://www.sciencedirect.com/science/article/pii/S0190962221016455?via%3DihubJournal of the American Academy of Dermatology385CryotherapyVismodegibBasal cell carcinomaPublication969b7cc2-4eeb-48c0-b0b4-eb93f794dd65virtual::251-1969b7cc2-4eeb-48c0-b0b4-eb93f794dd65virtual::251-1https://scholar.google.com.co/citations?user=Paic_C8AAAAJ&hl=esvirtual::251-10000-0001-9382-214Xvirtual::251-1ORIGINAL27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdfapplication/pdf132914https://repositorio.cuc.edu.co/bitstreams/53955e25-4c5f-4624-935f-8dab9832dedc/download550e3522ec17a3d3d54c52a37d12b17dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83196https://repositorio.cuc.edu.co/bitstreams/5439741f-4f1d-4c9b-8938-853c3947c3e9/downloade30e9215131d99561d40d6b0abbe9badMD52TEXT27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.txt27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.txttext/plain9474https://repositorio.cuc.edu.co/bitstreams/6a2e081b-1745-4b4a-9586-92dff3368e99/download472acd6d7e08130ceaf0b9fbcf350780MD53THUMBNAIL27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.jpg27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.jpgimage/jpeg15982https://repositorio.cuc.edu.co/bitstreams/8428aa3c-b116-43b8-8fac-b3d13a027389/download0f3750738f93bd00c645a6162cde60e7MD5411323/9307oai:repositorio.cuc.edu.co:11323/93072025-02-18 15:56:14.356https://creativecommons.org/licenses/by-nc-sa/4.0/© 2021 Published by Elsevier Inc.open.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.coQXV0b3Jpem8gKGF1dG9yaXphbW9zKSBhIGxhIEJpYmxpb3RlY2EgZGUgbGEgSW5zdGl0dWNpw7NuIHBhcmEgcXVlIGluY2x1eWEgdW5hIGNvcGlhLCBpbmRleGUgeSBkaXZ1bGd1ZSBlbiBlbCBSZXBvc2l0b3JpbyBJbnN0aXR1Y2lvbmFsLCBsYSBvYnJhIG1lbmNpb25hZGEgY29uIGVsIGZpbiBkZSBmYWNpbGl0YXIgbG9zIHByb2Nlc29zIGRlIHZpc2liaWxpZGFkIGUgaW1wYWN0byBkZSBsYSBtaXNtYSwgY29uZm9ybWUgYSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBxdWUgbWUobm9zKSBjb3JyZXNwb25kZShuKSB5IHF1ZSBpbmNsdXllbjogbGEgcmVwcm9kdWNjacOzbiwgY29tdW5pY2FjacOzbiBww7pibGljYSwgZGlzdHJpYnVjacOzbiBhbCBww7pibGljbywgdHJhbnNmb3JtYWNpw7NuLCBkZSBjb25mb3JtaWRhZCBjb24gbGEgbm9ybWF0aXZpZGFkIHZpZ2VudGUgc29icmUgZGVyZWNob3MgZGUgYXV0b3IgeSBkZXJlY2hvcyBjb25leG9zIHJlZmVyaWRvcyBlbiBhcnQuIDIsIDEyLCAzMCAobW9kaWZpY2FkbyBwb3IgZWwgYXJ0IDUgZGUgbGEgbGV5IDE1MjAvMjAxMiksIHkgNzIgZGUgbGEgbGV5IDIzIGRlIGRlIDE5ODIsIExleSA0NCBkZSAxOTkzLCBhcnQuIDQgeSAxMSBEZWNpc2nDs24gQW5kaW5hIDM1MSBkZSAxOTkzIGFydC4gMTEsIERlY3JldG8gNDYwIGRlIDE5OTUsIENpcmN1bGFyIE5vIDA2LzIwMDIgZGUgbGEgRGlyZWNjacOzbiBOYWNpb25hbCBkZSBEZXJlY2hvcyBkZSBhdXRvciwgYXJ0LiAxNSBMZXkgMTUyMCBkZSAyMDEyLCBsYSBMZXkgMTkxNSBkZSAyMDE4IHkgZGVtw6FzIG5vcm1hcyBzb2JyZSBsYSBtYXRlcmlhLg0KDQpBbCByZXNwZWN0byBjb21vIEF1dG9yKGVzKSBtYW5pZmVzdGFtb3MgY29ub2NlciBxdWU6DQoNCi0gTGEgYXV0b3JpemFjacOzbiBlcyBkZSBjYXLDoWN0ZXIgbm8gZXhjbHVzaXZhIHkgbGltaXRhZGEsIGVzdG8gaW1wbGljYSBxdWUgbGEgbGljZW5jaWEgdGllbmUgdW5hIHZpZ2VuY2lhLCBxdWUgbm8gZXMgcGVycGV0dWEgeSBxdWUgZWwgYXV0b3IgcHVlZGUgcHVibGljYXIgbyBkaWZ1bmRpciBzdSBvYnJhIGVuIGN1YWxxdWllciBvdHJvIG1lZGlvLCBhc8OtIGNvbW8gbGxldmFyIGEgY2FibyBjdWFscXVpZXIgdGlwbyBkZSBhY2Npw7NuIHNvYnJlIGVsIGRvY3VtZW50by4NCg0KLSBMYSBhdXRvcml6YWNpw7NuIHRlbmRyw6EgdW5hIHZpZ2VuY2lhIGRlIGNpbmNvIGHDsW9zIGEgcGFydGlyIGRlbCBtb21lbnRvIGRlIGxhIGluY2x1c2nDs24gZGUgbGEgb2JyYSBlbiBlbCByZXBvc2l0b3JpbywgcHJvcnJvZ2FibGUgaW5kZWZpbmlkYW1lbnRlIHBvciBlbCB0aWVtcG8gZGUgZHVyYWNpw7NuIGRlIGxvcyBkZXJlY2hvcyBwYXRyaW1vbmlhbGVzIGRlbCBhdXRvciB5IHBvZHLDoSBkYXJzZSBwb3IgdGVybWluYWRhIHVuYSB2ZXogZWwgYXV0b3IgbG8gbWFuaWZpZXN0ZSBwb3IgZXNjcml0byBhIGxhIGluc3RpdHVjacOzbiwgY29uIGxhIHNhbHZlZGFkIGRlIHF1ZSBsYSBvYnJhIGVzIGRpZnVuZGlkYSBnbG9iYWxtZW50ZSB5IGNvc2VjaGFkYSBwb3IgZGlmZXJlbnRlcyBidXNjYWRvcmVzIHkvbyByZXBvc2l0b3Jpb3MgZW4gSW50ZXJuZXQgbG8gcXVlIG5vIGdhcmFudGl6YSBxdWUgbGEgb2JyYSBwdWVkYSBzZXIgcmV0aXJhZGEgZGUgbWFuZXJhIGlubWVkaWF0YSBkZSBvdHJvcyBzaXN0ZW1hcyBkZSBpbmZvcm1hY2nDs24gZW4gbG9zIHF1ZSBzZSBoYXlhIGluZGV4YWRvLCBkaWZlcmVudGVzIGFsIHJlcG9zaXRvcmlvIGluc3RpdHVjaW9uYWwgZGUgbGEgSW5zdGl0dWNpw7NuLCBkZSBtYW5lcmEgcXVlIGVsIGF1dG9yKHJlcykgdGVuZHLDoW4gcXVlIHNvbGljaXRhciBsYSByZXRpcmFkYSBkZSBzdSBvYnJhIGRpcmVjdGFtZW50ZSBhIG90cm9zIHNpc3RlbWFzIGRlIGluZm9ybWFjacOzbiBkaXN0aW50b3MgYWwgZGUgbGEgSW5zdGl0dWNpw7NuIHNpIGRlc2VhIHF1ZSBzdSBvYnJhIHNlYSByZXRpcmFkYSBkZSBpbm1lZGlhdG8uDQoNCi0gTGEgYXV0b3JpemFjacOzbiBkZSBwdWJsaWNhY2nDs24gY29tcHJlbmRlIGVsIGZvcm1hdG8gb3JpZ2luYWwgZGUgbGEgb2JyYSB5IHRvZG9zIGxvcyBkZW3DoXMgcXVlIHNlIHJlcXVpZXJhIHBhcmEgc3UgcHVibGljYWNpw7NuIGVuIGVsIHJlcG9zaXRvcmlvLiBJZ3VhbG1lbnRlLCBsYSBhdXRvcml6YWNpw7NuIHBlcm1pdGUgYSBsYSBpbnN0aXR1Y2nDs24gZWwgY2FtYmlvIGRlIHNvcG9ydGUgZGUgbGEgb2JyYSBjb24gZmluZXMgZGUgcHJlc2VydmFjacOzbiAoaW1wcmVzbywgZWxlY3Ryw7NuaWNvLCBkaWdpdGFsLCBJbnRlcm5ldCwgaW50cmFuZXQsIG8gY3VhbHF1aWVyIG90cm8gZm9ybWF0byBjb25vY2lkbyBvIHBvciBjb25vY2VyKS4NCg0KLSBMYSBhdXRvcml6YWNpw7NuIGVzIGdyYXR1aXRhIHkgc2UgcmVudW5jaWEgYSByZWNpYmlyIGN1YWxxdWllciByZW11bmVyYWNpw7NuIHBvciBsb3MgdXNvcyBkZSBsYSBvYnJhLCBkZSBhY3VlcmRvIGNvbiBsYSBsaWNlbmNpYSBlc3RhYmxlY2lkYSBlbiBlc3RhIGF1dG9yaXphY2nDs24uDQoNCi0gQWwgZmlybWFyIGVzdGEgYXV0b3JpemFjacOzbiwgc2UgbWFuaWZpZXN0YSBxdWUgbGEgb2JyYSBlcyBvcmlnaW5hbCB5IG5vIGV4aXN0ZSBlbiBlbGxhIG5pbmd1bmEgdmlvbGFjacOzbiBhIGxvcyBkZXJlY2hvcyBkZSBhdXRvciBkZSB0ZXJjZXJvcy4gRW4gY2FzbyBkZSBxdWUgZWwgdHJhYmFqbyBoYXlhIHNpZG8gZmluYW5jaWFkbyBwb3IgdGVyY2Vyb3MgZWwgbyBsb3MgYXV0b3JlcyBhc3VtZW4gbGEgcmVzcG9uc2FiaWxpZGFkIGRlbCBjdW1wbGltaWVudG8gZGUgbG9zIGFjdWVyZG9zIGVzdGFibGVjaWRvcyBzb2JyZSBsb3MgZGVyZWNob3MgcGF0cmltb25pYWxlcyBkZSBsYSBvYnJhIGNvbiBkaWNobyB0ZXJjZXJvLg0KDQotIEZyZW50ZSBhIGN1YWxxdWllciByZWNsYW1hY2nDs24gcG9yIHRlcmNlcm9zLCBlbCBvIGxvcyBhdXRvcmVzIHNlcsOhbiByZXNwb25zYWJsZXMsIGVuIG5pbmfDum4gY2FzbyBsYSByZXNwb25zYWJpbGlkYWQgc2Vyw6EgYXN1bWlkYSBwb3IgbGEgaW5zdGl0dWNpw7NuLg0KDQotIENvbiBsYSBhdXRvcml6YWNpw7NuLCBsYSBpbnN0aXR1Y2nDs24gcHVlZGUgZGlmdW5kaXIgbGEgb2JyYSBlbiDDrW5kaWNlcywgYnVzY2Fkb3JlcyB5IG90cm9zIHNpc3RlbWFzIGRlIGluZm9ybWFjacOzbiBxdWUgZmF2b3JlemNhbiBzdSB2aXNpYmlsaWRhZA== |